In BioVie’s Phase 2 Trial, Bezisterim is Safe and Reduces Neurological Symptoms of Long Covid
BioVie, a pharmaceutical company developing treatments for neurological diseases, recently announced results from its phase
November 9, 2026
BioVie, a pharmaceutical company developing treatments for neurological diseases, recently announced results from its phase
Solve’s Ramsay Research Grants and ME/CFS Catalyst Award programs have achieved an impressive 66x return on investment, demonstrating
In our 2026 State of the ME/CFS Union Address, Solve M.E. leadership shared a vision
Solve M.E.released the following statement in response to news reports that the administration is drafting
BioVie announced promising results from the ADDRESS-LC trial assessing the potential impact of the drug
The National Institute of Allergy and Infectious Diseases (NIAID) has proposed a reorganization that would
Today, we’re saying a big thank you to our Members of Congress. By passing a
We learned this week of the passing of a beloved member of the Solve community,
Dr. Rob Wüst, physiology professor at the Vrije de Universiteit (Netherlands) and winner of a
Dr. David Esteban is a professor of biology at Vassar College. He specializes in understanding
We wanted to provide an update on Solve M.E.’s recent advocacy campaign opposing the proposed
This quarter’s summaries highlight several studies examining the biological mechanisms of ME/CFS and Long Covid,
